4.4 Article

Low vitamin D level is an independent predictor of poor outcomes in Clostridium difficile-associated diarrhea

期刊

出版社

SAGE PUBLICATIONS LTD
DOI: 10.1177/1756283X13502838

关键词

Clostridium difficile enteritis; clostridium difficile diarrhea; vitamin D; hypovitaminosis D; recurrent clostridium difficile

向作者/读者索取更多资源

Background: The incidence, recurrence, and all-cause mortality rate for Clostridium difficile-associated diarrhea (CDAD) has increased markedly over the past 10 years despite treatment. Low vitamin D levels are known to impair immune responses to infection and are associated with increased mortality. We compared the role of patient comorbidity measured by the Charlson Comorbidity Index (CCI) with vitamin D levels to ascertain whether vitamin D levels were an independent variable affecting the outcome of CDAD or a marker of overall comorbidity. Methods: A prospective cohort study studied 62 patients hospitalized between 2008 and 2009 with manifestations of CDAD and a positive C. difficile toxin assay. All patients received standard antibiotics (metronidazole and/or vancomycin). Their status at 30-day follow up was classified as resolved or recurred/expired. Patients CCI was calculated using their medical history. Logistic regression analysis of variables including 25-hydroxyvitamin D, CCI, age, gender, white blood cell count (WBC), albumin and residence type were performed. Results: There were 62 patients (43.6% men, 56.4% women) with CDAD; mean age was 75 +/- 17 years. At 30-day follow up, 28 (45.2%) expired, 10 (16.1%) had persistent or recurrent diarrhea and 24 (38.7%) resolved. Nonresolution was seen in 38 (61.3%). There was no significant association between 30-day resolution status and CCI, gender, WBC, albumin level or residence type. Two variables were found to be independent predictors of resolution of CDAD: normal vitamin D levels (p = 0.028) and age < 70 years (p = 0.024). Subjects with low vitamin D were 4.75 times more likely to fail to resolve CDAD than subjects with normal Vitamin D. Conclusion: In this study, vitamin D level and age are independent predictors of CDAD resolution in hospitalized patients. Low vitamin D levels and age > 70 years old are associated with increased likelihood of recurrence. Low vitamin D levels are not a marker of comorbidity or advanced age.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Urology & Nephrology

Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747)

Lazaros Andronis, Ilias Goranitis, Sarah Pirrie, Ann Pope, Darren Barton, Stuart Collins, Adam Daunton, Duncan McLaren, Joe M. O'Sullivan, Chris Parker, Emilio Porfiri, John Staffurth, Andrew Stanley, James Wylie, Sharon Beesley, Alison Birtle, Janet E. Brown, Prabir Chakraborti, Syed A. Hussain, J. Martin Russell, Lucinda J. Billingham, Nicholas D. James

BJU INTERNATIONAL (2017)

Article Oncology

Cisplatin-Versus Non-Cisplatin-based First-Line Chemotherapy for Advanced Urothelial Carcinoma Previously Treated With Perioperative Cisplatin

Jennifer A. Locke, Gregory Russell Pond, Guru Sonpavde, Andrea Necchi, Patrizia Giannatempo, Ravi Kumar Paluri, Guenter Niegisch, Peter Albers, Carlo Buonerba, Giuseppe Di Lorenzo, Ulka N. Vaishampayan, Scott A. North, Neeraj Agarwal, Syed A. Hussain, Sumanta Pal, Bernhard J. Eigl

CLINICAL GENITOURINARY CANCER (2016)

Review Oncology

Bladder Sparing Approaches for Muscle-Invasive Bladder Cancers

Omar M. S. El-Taji, Sameer Alam, Syed A. Hussain

CURRENT TREATMENT OPTIONS IN ONCOLOGY (2016)

Article Urology & Nephrology

A Randomised Phase 2 Study of AZD2014 Versus Everolimus in Patients with VEGF-Refractory Metastatic Clear Cell Renal Cancer

Thomas Powles, Matthew Wheater, Omar Din, Thomas Geldart, Ekaterini Boleti, Andrew Stockdale, Santhanam Sundar, Angus Robinson, Imtiaz Ahmed, Akhila Wimalasingham, Wendy Burke, Shah-Jalal Sarker, Syed Hussain, Christy Ralph

EUROPEAN UROLOGY (2016)

Article Oncology

Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1

Matthew Smith, Johann De Bono, Cora Sternberg, Sylvestre Le Moulec, Stephane Oudard, Ugo De Giorgi, Michael Krainer, Andries Bergman, Wolfgang Hoelzer, Ronald De Wit, Martin Boegemann, Fred Saad, Giorgio Cruciani, Antoine Thiery-Vuillemin, Susan Feyerabend, Kurt Miller, Nadine Houede, Syed Hussain, Elaine Lam, Jonathan Polikoff, Arnulf Stenzl, Paul Mainwaring, David Ramies, Colin Hessel, Aaron Weitzman, Karim Fizazi

JOURNAL OF CLINICAL ONCOLOGY (2016)

Article Oncology

The increased expression of fatty acid-binding protein 9 in prostate cancer and its prognostic significance

Majed Saad Al Fayi, Xiaojun Gou, Shiva S. Forootan, Waseem Al-Jameel, Zhengzheng Bao, Philip R. Rudland, Philip A. Cornford, Syed A. Hussain, Youqiang Ke

ONCOTARGET (2016)

Article Oncology

Fatty acid activated PPARγ promotes tumorigenicity of prostate cancer cells by up regulating VEGF via PPAR responsive elements of the promoter

Farzad S. Forootan, Shiva S. Forootan, Xiaojun Gou, Jin Yang, Bichong Liu, Danqing Chen, Majed Saad Al Fayi, Waseem Al-Jameel, Philip S. Rudland, Syed A. Hussain, Youqiang Ke

ONCOTARGET (2016)

Article Oncology

Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both The TRAPEZE Randomized Clinical Trial

Nicholas D. James, Sarah J. Pirrie, Ann M. Pope, Darren Barton, Lazaros Andronis, Ilias Goranitis, Stuart Collins, Adam Daunton, Duncan McLaren, Joe O'Sullivan, Christopher Parker, Emilio Porfiri, John Staffurth, Andrew Stanley, James Wylie, Sharon Beesley, Alison Birtle, Janet Brown, Prabir Chakraborti, Syed Hussain, Martin Russell, Lucinda J. Billingham

JAMA ONCOLOGY (2016)

Article Oncology

Gene expression profiling in bladder cancer identifies potential therapeutic targets

Syed A. Hussain, Daniel H. Palmeri, Wing-Kin Syn, Joseph J. Sacco, Richard M. D. Greensmith, Taha Elmetwali, Vijay Aachi, Bryony H. Lloyd, Puthen V. Jithesh, John Arrand, Darren Barton, Jawaher Ansari, D. Ross Sibson, Nicholas D. James

INTERNATIONAL JOURNAL OF ONCOLOGY (2017)

Article Oncology

Urological cancer patients receiving treatment during COVID-19: a single-centre perspective

Sophie Therese Williams, Salma El Badri, Syed Anwer Hussain

Summary: This retrospective case series found that administration of anticancer treatment did not result in an apparent increase in symptomatic COVID-19 infections in urological cancer patients at one centre.

BRITISH JOURNAL OF CANCER (2021)

Article Multidisciplinary Sciences

Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trial

Michiel S. van der Heijden, Thomas Powles, Daniel Petrylak, Ronald de Wit, Andrea Necchi, Cora N. Sternberg, Nobuaki Matsubara, Hiroyuki Nishiyama, Daniel Castellano, Syed A. Hussain, Aristotelis Bamias, Georgios Gakis, Jae-Lyun Lee, Scott T. Tagawa, Ulka Vaishampayan, Jeanny B. Aragon-Ching, Bernie J. Eigl, Rebecca R. Hozak, Erik R. Rasmussen, Meng Summer Xia, Ryan Rhodes, Sameera Wijayawardana, Katherine M. Bell-McGuinn, Amit Aggarwal, Alexandra Drakaki

Summary: This study identifies potential predictive biomarkers for survival benefit in patients with platinum-refractory advanced urothelial carcinoma treated with the anti-VEGFR2 monoclonal antibody ramucirumab. Higher PD-L1 IHC and immune pathway scores are associated with greater ramucirumab overall survival (OS) benefit. Basal molecular subtypes show greater OS benefit compared to Luminal subtypes. Patients from East Asia have lower immune/angiogenesis signature scores, correlating with decreased ramucirumab OS benefit. The study highlights the importance of multiple biomarkers in identifying patients who might benefit the most from treatment with ramucirumab.

NATURE COMMUNICATIONS (2022)

Article Oncology

A Phase Ib/II study of IGF-neutralising antibody xentuzumab with enzalutamide in metastatic castration-resistant prostate cancer

Valentine M. Macaulay, Simon Lord, Syed Hussain, Jose Pablo Maroto, Robert Hugh Jones, Miguel Angel Climent, Natalie Cook, Chia-Chi Lin, Shian-Shiang Wang, Diletta Bianchini, Mark Bailey, Laura Schlieker, Thomas Bogenrieder, Johann de Bono

Summary: This study evaluated the combination therapy of xentuzumab and enzalutamide in patients with metastatic castrate-resistant prostate cancer. The results showed that the combination treatment had some efficacy in certain patients.

BRITISH JOURNAL OF CANCER (2023)

Article Urology & Nephrology

Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study

Andrea Necchi, Gregory R. Pond, Marc C. Smaldone, Sumanta K. Pal, Kevin Chan, Yu-Ning Wong, Rosalia Viterbo, Guru Sonpavde, Lauren C. Harshman, Simon Crabb, Ajjai Alva, Simon Chowdhury, Ugo De Giorgi, Sandy Srinivas, Neeraj Agarwal, Aristotelis Bamias, Jack Baniel, Ali-Reza Golshayan, Sylvain Ladoire, Cora N. Sternberg, Linda Cerbone, Evan Y. Yu, Joaquim Bellmunt, Ulka Vaishampayan, Gunter Niegisch, Syed Hussain, Daniel W. Bowles, Rafael Morales-Barrera, Matthew I. Milowsky, Christine Theodore, Dominik R. Berthold, Srikala S. Sridhar, Thomas Powles, Jonathan E. Rosenberg, Matthew D. Galsky

EUROPEAN UROLOGY FOCUS (2018)

Article Oncology

The predictive and prognostic value of tumour necrosis in muscle invasive bladder cancer patients receiving radiotherapy with or without chemotherapy in the BC2001 trial (CRUK/01/004)

Ananya Choudhury, Catharine M. West, Nuria Porta, Emma Hall, Helen Denley, Carey Hendron, Rebecca Lewis, Syed A. Hussain, Robert Huddart, Nicholas James

BRITISH JOURNAL OF CANCER (2017)

暂无数据